Elevance Health, Inc. $ELV Stock: Sanders Capital LLC Raises Holdings

Sanders Capital LLC boosted its position in Elevance Health, Inc. (NYSE:ELV) by 0.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,830,605 shares of the company’s stock after buying an additional 5,581 shares during the period. Elevance Health makes up approximately 2.2% of Sanders Capital LLC’s portfolio, making the stock its 14th biggest position. Sanders Capital LLC owned approximately 2.70% of Elevance Health worth $2,267,056,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Field & Main Bank grew its stake in Elevance Health by 1.3% in the second quarter. Field & Main Bank now owns 1,883 shares of the company’s stock valued at $728,000 after acquiring an additional 25 shares during the period. Simplicity Wealth LLC increased its holdings in shares of Elevance Health by 1.3% during the third quarter. Simplicity Wealth LLC now owns 1,939 shares of the company’s stock valued at $754,000 after acquiring an additional 25 shares in the last quarter. Tranquilli Financial Advisor LLC raised its position in shares of Elevance Health by 1.3% during the second quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company’s stock worth $805,000 after purchasing an additional 26 shares during the period. Mather Group LLC. raised its position in shares of Elevance Health by 3.5% during the third quarter. Mather Group LLC. now owns 766 shares of the company’s stock worth $298,000 after purchasing an additional 26 shares during the period. Finally, 55 North Private Wealth LLC lifted its holdings in shares of Elevance Health by 4.5% in the 3rd quarter. 55 North Private Wealth LLC now owns 598 shares of the company’s stock worth $233,000 after purchasing an additional 26 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Elevance Health news, EVP Ratnakar Lavu sold 1,300 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $440.00, for a total value of $572,000.00. Following the completion of the transaction, the executive vice president owned 14,849 shares in the company, valued at $6,533,560. This represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Kaye sold 10,584 shares of the firm’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the sale, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. This represents a 34.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.34% of the stock is owned by corporate insiders.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Elevance Health Stock Down 1.4%

NYSE:ELV traded down $5.83 on Friday, hitting $426.17. The stock had a trading volume of 1,443,875 shares, compared to its average volume of 1,442,885. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47. The stock has a market cap of $92.08 billion, a P/E ratio of 18.17, a price-to-earnings-growth ratio of 1.97 and a beta of 0.63. Elevance Health, Inc. has a 1 year low of $274.84 and a 1 year high of $450.69. The firm’s fifty day simple moving average is $412.92 and its two-hundred day simple moving average is $373.58.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. The firm had revenue of $50.44 billion for the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.03 EPS. Analysts predict that Elevance Health, Inc. will post 29.16 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a $1.72 dividend. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 annualized dividend and a yield of 1.6%. Elevance Health’s payout ratio is currently 29.34%.

Analysts Set New Price Targets

Several research firms recently issued reports on ELV. Truist Financial lifted their price target on shares of Elevance Health from $450.00 to $475.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Morgan Stanley boosted their price target on shares of Elevance Health from $404.00 to $449.00 and gave the company an “equal weight” rating in a research note on Thursday, October 22nd. Wells Fargo & Company upped their price objective on shares of Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a report on Tuesday, October 27th. Guggenheim raised their price objective on shares of Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Finally, Royal Bank Of Canada lifted their price objective on shares of Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a report on Thursday, October 22nd. Fifteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $456.48.

Elevance Health Company Profile

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.